Dear Investors, Welcome to Germany! It is our pleasure to present you with information about investment opportunities in Germany’s thriving biotechnology sector.

The German biotech industry continues to play a leading role in Europe, both in terms of corporate representation and capacity to generate new intellectual property. Invigorated by a phase of healthy consolidation, biotech companies in Germany are launching exciting new products and have many more in the pipeline. These companies have gained maturity and are once again demonstrating their ability to raise capital. While highly renowned program funds actively support early-stage enterprises, the venture capital industry is raising additional funding to help promising companies grow.

This should serve as an invitation to enter the German biotech market and reap the rewards of Germany as a business location in general.

It’s our goal and commitment at Invest in Germany to assist you in setting up your business in our country. With our multifaceted network involving industry, government and academia we are in an excellent position to help you profit from biotechnology “Made in Germany”.

We look forward to working with you.

Dr. Horst Dietz
Managing Director
Invest in Germany GmbH

Download Biotech "Made in Germany": From Start-up to Grown-up

PDF format, 1.5MB, 20 Pages. Provided by INVEST IN GERMANY.

LATEST SUCCESS STORIES
Healthcare Biotechnology

Researchers in Munich and Bonn have reported a major breakthrough in decoding the mechanism of immune defense. Under the direction of professor Gunther Hartmann, a team of researchers from the clinical pharmacology departments of Bonn University Clinic and Munich University Clinic are doing work that could fundamentally change our understanding of viral infections.

The Helmholtz Centre for Infection Research (formerly the German Research Center for Biotechnology) has begun cooperating with the international healthcare company Roche to develop an improved method for antibody production. Research is focusing on the use of animal cells to produce antibodies.

A team of scientists from France, Portugal and Germany have reported the development of a new type of cell that can continuously produce retroviral virus particles in large and specific quantities. Researchers from The Helmholtz Center for Infection Research are helping to develop these “high-performance” cells for gene therapy.

An international consortium coordinated by Prof. Stefan H.E. Kaufmann, director at the Max Planck Institute for Infection Biology in Berlin, has received a 13 million-dollar grant from the Bill & Melinda Gates Foundation to identify the molecular defence mechanisms responsible for protection against tuberculosis. Identifying these biomarkers would be of enormous value in designing and testing an improved vaccine.

Scientists in Germany are reporting significant progress in describing the structural basis of protein sorting and translocation involving large macromolecular complexes. The work is being done by professor Roland Beckmann at the Gene Center at the LMU, Munich in cooperation with the University of Heidelberg and Berlin’s Max-Planck Institute for Molecular Genetics.

The Fraunhofer Institute for Interfacial Engineering and Biotechnology is collaborating with the Robert Bosch hospital in Stuttgart and the Universities of Stuttgart and Tübingen to develop and test a biochip that will help accurately diagnosis breast tumors. The chip utilizes a sophisticated form of gene profiling.

Germany’s eastern states are now home to more than 300 life science companies. The region, which has struggled to rebuild its economy in the wake of reunification, has succeeded in attracting a wide range of biotech-related firms involved in everything from functional genomics to tissue engineering.

INVEST IN GERMANY SERVICES
For start-ups and grown-ups

Invest in Germany’s mission is to promote Germany as a location for business, investment, and technology and to actively identify business opportunities for international investors. Invest in Germany works to translate the country’s competitive advantages into mutually beneficial success, drawing investment and jobs to Germany.

We actively encourage cross-border investment into Germany from all spheres – public and private, corporate and institutional. Our services are available free of charge to embassies, trade organizations, industrial groups, business leaders and research institutions.

Our task is three-fold: first, to develop contacts with potential foreign investors; second, to identify business opportunities for them in Germany; and third, to facilitate the successful execution of the investment project.

Matching the needs of specific industries, our services include:
Local partner search
Market research
Incentive advice
Site selection support

For investors in the life sciences sector we have assembled a multilingual team of highly trained professionals. Backed by a staff of legal and economic advisors, they provide clients with all the resources they need, supporting investment projects from start to finish.

---

Write Comment
Please keep the topic of messages relevant to the subject of the article. Personal verbal attacks will be deleted.
Name:
E-mail
Homepage
Title:
BBCode:
Comment:
Code:*

Powered by AkoComment!